摘要
背景高血压与心血管疾病发病和死亡风险间存在密切的因果关系,降压宝系列中成药对于治疗原发性高血压病有较好的疗效。目的评价长期服用降压宝系列中成药对高血压患者结局的影响。方法采用队列研究,选取2001—2003年于河南省高血压中西医结合诊疗中心就诊的1 364例原发性高血压病患者为研究对象。均进行高血压的标准二级预防措施并服用降压宝系列中成药,利用受试者脱离服药自然形成的队列差,以服药总月数42个月为标准分为短期服药组236例和长期服药组1 128例。收集年龄、高血压早发家族史、病程、血压级别、抗高血压西药使用情况、吸烟史、饮酒史、文化水平、运动量、睡眠状况等资料,连续追踪调查42个月,记录不良结局(心脑血管死亡、心肌梗死、脑梗死、脑出血等)的发生情况。采用Cox比例风险回归模型分析长期服用降压宝系列中成药对高血压患者结局的影响。结果入组患者不良结局发生率为15.90%(217/1 364),2001、2002、2003年入组患者的不良反应发生率分别为22.22%(80/360)、13.06%(64/490)、14.20%(73/514)。至试验结束,长期服药组不良结局发生率低于短期服药组,差异有统计学意义[10.17%(24/236)比17.11%(193/1 128),χ~2=7.03,P=0.008]。Cox比例风险回归分析结果显示,在不同回归模型中,短期服药组不良结局发生率均高于长期服药组(HR均>1.00,P均<0.05)。结论长期服用降压宝系列中成药能明显降低高血压患者不良结局的发生率。
Background There is a close causal relationship between hypertension and the risk of cardiovascular disease morbidity and mortality.Jiangyabao series of Chinese patent medicines(a sort of hypotensors)have good effects on essential hypertension.Objective To evaluate the effect of long-term administration of Jiangyabao series of Chinese patent medicines on the outcome of patients with hypertension.Methods This study was carried out from 2001 to 2003 based on a cohort design.The 1 364 participants with essential hypertension were recruited from Henan Hypertension Management Center of Integrated Traditional Chinese and Western Medicine.All of them received standardized secondary prevention interventions for hypertension and oral administration of Jiangyabao series of Chinese patent medicines.In accordance with the duration of voluntary administration,they were assigned to short-term medication group(n=236,≤42 months),long-term medication group(n=1 128,>42 months),respectively.Data of age,family history of early onset of hypertension,duration of hypertension,stage of hypertension,use of western antihypertensive drugs,smoking history,drinking history,education level,amount of exercise and sleeping status were collected.All of them were followed up for 42 months,during which the incidence of adverse outcomes(death caused by cardiovascular and cerebrovascular diseases,myocardial infarction,cerebral infarction,cerebral hemorrhage)was recorded.Cox proportional hazards regression analysis was used to analyze the effect of long-term administration of Jiangyabao series of Chinese patent medicines on the outcome.Results The incidence of adverse outcomes in new included participants during the whole study period was 15.90%(217/1 364),and 22.22%(80/360),13.06%(64/490)and 14.20%(73/514)in 2001,2002 and 2003.By the end of the experiment,the incidence of adverse outcomes in the long-term medication group was lower than that in the short-term medication group〔10.17%(24/236)vs 17.11%(193/1 128),χ2=7.03,P=0.008〕.Analyses with different Cox proportional risk regression models showed that the incidence of adverse outcomes in short-term medication group was higher than that of the long-term medication group(HR>1.00,P<0.05).Conclusion Long-term administration of Jiangyabao series of Chinese patent medicines can significantly reduce the incidence of adverse outcomes in patients with hypertension.
作者
崔伟锋
范小会
王守富
范军星
武可文
邓松涛
范军铭
CUI Weifeng;FAN Xiaohui;WANG Shoufu;FAN Junxing;WU Kewen;DENG Songtao;FAN Junming(Henan Province Chinese Medicine Research Institute,Zhengzhou 450004,China;Health Statistics and Information Center,Health Commission of Henan Province,Zhengzhou 450004,China)
出处
《中国全科医学》
CAS
北大核心
2019年第1期101-105,共5页
Chinese General Practice
基金
国家自然科学基金资助项目(81273877)
河南省科技攻关项目(162102310063)
河南省中医临床学科领军人才(2013-10)
河南省中医药科学研究专项重点项目(2013ZY01002)
关键词
高血压
降压宝系列中成药
Cox比例风险回归
队列研究
Hypertension
Jiangyabao Chinese patent medicine series
Cox proportional risk regression
Cohort study
